The effect of myrislignan on GBM was confirmed in vivo in the intracranial xenograft model; in particular, Western blot analysis and IHC staining demonstrated that expression of p-p65, Slug, and SLC7A11 declined in myrislignan-treated tumors. This evidence concerns the gene SNAI2 and glioblastoma.